Skip to content
S8991Senate2023-2024 SessionSame asA8075

Expand Access to Naloxone

Official title

“Relates to the availability of opioid reversal agents”

Sponsor Pete HarckhamSD-40+5 co-sponsorsAffects Health
Status
In Senate Committee
Alcoholism And Substance Use Disorders
Impact
7/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Alcoholism And Substance Use Disorders

What's happening

This bill expands access to all FDA-approved opioid reversal agents, requiring cost coverage for nasal naloxone and updating public directories.

Why it matters

  1. Broader access to life-saving drugs. By expanding the definition from just “naloxone” to all FDA-approved opioid reversal agents, the bill ensures that communities have access to the latest and most effective treatments for opioid overdoses as they become available.

  2. Cost coverage for nasal naloxone. The state will be required to cover the full cost of any FDA-approved nasal naloxone formulation, reducing cost barriers for the most widely used, user-friendly overdose reversal method.

  3. Transparency and choice for providers and communities. Directories will now clearly list which specific opioid reversal agents are available at each distribution point, and providers can choose any FDA-approved formulation or dosage, supporting personalized and flexible overdose prevention.

  4. Shared cost for alternatives. If a purchaser (like a community group or hospital) opts for a reversal agent that is more expensive than the highest-priced nasal naloxone, they will be responsible for the extra cost, incentivizing cost-effective choices while still allowing access to more expensive options if needed.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • State health and substance use agencies

    The bill would require them to allow a choice of any FDA-approved formulation and dosage of opioid reversal agents, with the Department of Health covering FDA-approved nasal naloxone products.

  • Community organizations and municipalities

    Those accessing reversal drugs through the state standing order would gain product choices but would bear costs above the highest-priced nasal naloxone product for other products.

  • Pharmacies, hospitals and medical facilities

    The bill would expand their choice of opioid reversal agents when purchasing through the state standing order.

  • People seeking opioid reversal agents

    The bill would require the state's searchable distributor directory to identify which reversal agents are currently available at each location.

Headline styles

Expand Access to Naloxone

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Pete Harckham

Senator · Senate District 40

Chair, Environmental Conservation

History

  1. Print number 8991a
  2. Amend and recommit to alcoholism and substance use disorders
  3. Referred to alcoholism and substance use disorders

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A8075Assembly

Expand Opioid Reversal Access

In Senate Committee · Rules · Sponsor Phil Steck

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

8991--A

IN SENATE

April 8, 2024

Introduced by Sens. HARCKHAM, ASHBY, COONEY, GALLIVAN, OBERACKER -- read twice and ordered printed, and when printed to be committed to the Committee on Alcoholism and Substance Use Disorders -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the mental hygiene law and the public health law, in relation to the availability of opioid reversal agents

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subdivision (l) of section 19.09 of the mental hygiene law, as added by chapter 434 of the laws of 2021, is amended to read as follows:

(l)(1) The office, in consultation with the department of health, shall maintain on its website a publicly available directory of all distributors of opioid [antagonists] reversal agents to the public, including but not limited to, pharmacies, prevention programs and notfor-profits. As used in this subdivision, the following terms shall have the following meanings:

(i) "Opioid" means an opiate as defined in section thirty-three hundred two of the public health law.

(ii) "Opioid [antagonist] reversal agents" means a federal food and drug administration-approved drug that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body. The [opioid antagonist shall be limited to naloxone or other medications approved by the department of health for this purpose] department of health shall make available any formulation and dosage of opioid reversal agents that are approved by the federal food and drug administration.

(iii) "Purchaser" means any community organization, municipality, pharmacy, medical facility, hospital, or any other entity, that accesses opioid reversal drugs through the New York state standing order.

(2) The directory required by this subdivision shall include and be searchable by the following information:

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD11983-07-4

(i) addresses of each distributor of opioid [antagonists] reversal agents;

(ii) contact information, such as phone numbers or email addresses, for each distributor;

(iii) services offered by each distributor at each location if more than one, as well as information providing which opioid [antagonists] reversal agents are currently available at each distributor;

(iv) special populations served;

(v) insurance providers accepted;

(vi) hours of operation of each distributor;

(vii) contact information of opioid addiction prevention programs; and

(viii) any other information the commissioner deems necessary.

(3) The office may utilize an existing directory to satisfy the requirements of this subdivision.

(4) The office shall allow for choice of any formulation and dosage of opioid reversal agents that are approved by the federal food and drug administration in the purchase, distribution or authorization to prescribe or dispense such products. The department shall cover the cost of any formulation and/or dosage of any federal food and drug administration-approved nasal naloxone product. Any other product where the cost exceeds that of highest-priced nasal naloxone product, that cost overrun shall be borne by the purchaser.

§ 2. Subparagraph (i) of paragraph (a) of subdivision 3 of section 3309 of the public health law, as amended by chapter 42 of the laws of 2014, is amended to read as follows:

(i) "Opioid [antagonist] reversal agents" means a drug approved by the Food and Drug Administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body. ["Opioid antagonist reversal agents" shall be limited to naloxone and other medications approved by the department for such purpose] The department shall make available any formulation and dosage of opioid reversal agents that are approved by the federal Food and Drug Administration.

§ 3. Section 3309 of the public health law is amended by adding a new subdivision 9 to read as follows:

9. Any purchase, distribution or authorization to prescribe pursuant to this section by the commissioner shall allow for choice of any formulation or dosage that is approved by the federal Food and Drug Administration. The department shall cover the cost of any formulation and/or dosage of any federal Food and Drug Administration-approved nasal naloxone product. Any other product where the cost exceeds that of highestpriced nasal naloxone product, that cost overrun shall be borne by the purchaser.

§ 4. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the mental hygiene law and the public health law, in relation to the availability of opioid reversal agents

Purpose or general idea or bill

Provide access to all formulations and doses of opioid reversal agents approved the Federal Drug and Administration

Summary of provisions

Section 1 amends subdivision (1) of Section 19.09 of the Mental Hygiene Law to require the Department of Health to make available any formu- lation and dosage of opioid reversal agents that are approved by the Federal Food and Drug Administration.

Read the full memo (654 words)

Section 2 amends section 25.18 of the Mental Hygiene Law to require any expenditures for the purchase or distribution of opioid reversal agents shall allow for any formulation or dosage that is approved by the Feder- al Food and Drug Administration.

Section 3 amends subparagraph (i) of paragraph (a) of subdivision 3 of section 3309 of the Public Health Law to include in the definition of opioid reversal agents and require the Department of Health to make available any formulation and dosage approved by the Federal Food and Drug Administration.

Section 4 adds a new subdivision of Section 3309 of the Public Health Law pertaining to opioid overdose prevention to require that any purchase, distribution or authorization to prescribe opioid reversal agents as authorized shall allow for choice of any formulation or dosage that is approved by the Federal Food and Drug Administration.

Justification

This legislation is critically important as New York continues to confront an alarming increase in the rate of overdose deaths. Data from the CDC reports that the share of drug overdose deaths in the State involving opioids increased to 85% in 2020 and 2021 from 69% in 2010, and overdose fatalities grew across all racial and ethnic groups. Death rates increased five-fold for Black New Yorkers, quadrupled for Hispanic or Latino New Yorkers, and nearly tripled for white New Yorkers. In 2021, 30 out of every 100,000 New Yorkers lost their lives to drug over- doses; of that, 30, 25 died specifically from opioid overdoses. A stag- gering rise from 2010, which saw 5 opioid-related deaths per 100,000 residents.

This public health crisis has evolved and continues to grow significant- ly. The transition from prescription drugs to heroin, and now predomi- nantly to fentanyl, a synthetic opioid is responsible for a substantial portion of overdose incidents in recent years. Synthetic opioids, espe- cially fentanyl, present a formidable challenge due to their unparal- leled potency-up to 50 times stronger than heroin and 100 times more potent than morphine. The numbers in New York are striking, with synthetic opioid-related overdoses, mainly due to fentanyl, rising from just 18 cases in 1999 to 4,950 in 2022. As we work to develop effective strategies to reduce overdose fatalities, it is essential that all communities in New York State have access to every life-saving FDA-ap- proved opioid reversal agent.

As the Food and Drug Administration continues to approve various formu- lations and dosages of FDA-approved opioid reversal agents to combat the rise of synthetic opioid overdose, it becomes essential for New York to offer the flexibility to make all formulations and dosages readily available. This approach aligns with a 2020 advisory from the CDC, which was directed at first responders, harm reduction organizations, and other stakeholders. The CDC's recommendations include the imperative to "expand distribution and use of FDA-approved opioid reversal agents and overdose prevention education." Increasing the resources accessible to first responders and individuals within the community is of paramount importance, particularly considering that 40% of all overdoses occur in the presence of another individual.

This legislation will ensure that New York State is equipped with a comprehensive toolkit to effectively combat the overdose crisis and the surge in synthetic opioids, which is profoundly impacting communities and families across the state.

Prior legislative history

New Bill

Fiscal implications

TBD

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.